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Overview on the pathomechanisms of allergic 
rhinitis 
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*, Sachiko mori, Chika Ozu, and Satoko Kimura
Nippon medical School, tokyo 113-8603, Japan
Allergic rhinitis a chronic inflammatory disease of the upper airways that has a major impact on the quality of life of patients and 
is a socio-economic burden. Understanding the underlying immune mechanisms is central to developing better and more targeted 
therapies. The inflammatory response in the nasal mucosa includes an immediate IgE-mediated mast cell response as well as a late-
phase response characterized by recruitment of eosinophils, basophils, and T cells expressing Th2 cytokines including interleukin (IL)-
4, a switch factor for IgE synthesis, and IL-5, an eosinophil growth factor and on-going allergic inflammation. Recent advances have 
suggested new pathways like local synthesis of IgE, the IgE-IgE receptor mast cell cascade in on-going allergic inflammation and 
the epithelial expression of cytokines that regulate Th2 cytokine responses (i.e., thymic stromal lymphopoietin, IL-25, and IL-33). In 
this review, we briefly review the conventional pathways in the pathophysiology of allergic rhinitis and then elaborate on the recent 
advances in the pathophysiology of allergic rhinitis. An improved understanding of the immune mechanisms of allergic rhinitis can 
provide a better insight on novel therapeutic targets.
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INTRODUCTION 
Since the discovery of IgE there has been an explosive increase 
in knowledge about how IgE is generated and its role in driving 
mast cell, basophil and eosinophil mediated inflammatory 
responses underlying allergic disorders. Principal among these 
responses are the production of cytokines, chemokines and 
adhesion molecules associated with the Th2 profile, the release 
of a variety of preformed and newly generated mediators from 
mast cells, and the selective recruitment and activation of 
secondary effector cells, particularly eosinophils and basophils. 
Allergic rhinitis (AR) is the most common of all allergic disease 
affecting approximately 400 million people worldwide and is 
associated with a reduced quality of life of the patients, lower 
work productivity and school learning performance as well as 
increasing medical costs [1-6]. Allergic rhinitis is an IgE-mediated 
inflammatory disease of the nasal mucous membranes due to 
the interaction of allergen characterized by an inflammatory 
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infiltrate made up of eosinophils, T cells, mast cells and basophils, 
which release several mediators, chemokines and cytokines 
(among these, histamine and cysteinyl-leukotrienes are the major 
vasoactive mediators), regulation of the local and systemic IgE 
synthesis, and communication with the immune system and the 
bone marrow [7]. Clinically this results in the typical symptoms 
of rhinorrhea, sneezing, itching and nasal blockage. Systemic 
circulation of inflammatory cells allows their infiltration into other 
tissues where chemoattractant and adhesion molecules already 
exist. Thus, besides local inflammation, AR also triggers a systemic 
inflammation, which can in turn augment inflammation in both 
the upper and lower airways. Consequently, AR is linked to various 
comorbid conditions: asthma, rhinosinusitis, nasal polyposis and 
serous otitis media and sleep disorders [8, 9] (Fig. 1).
Genetics and epigenetics
Allergic rhinitis typically starts in early childhood with the 
symptoms usually peaking in the second, third, and fourth 
decades of life. However, an onset of this disease in infancy or 
later in adults is not quite uncommon. Like other atopic diseases, 
in allergic rhinitis multiple family members often are affected. 
Although genetic determinants of total IgE levels and specific 
allergen sensitization are suggested, neither the form of atopic 
illness nor specific sensitivities seem to be heritable as simple 
genetic traits. Although there are several studies of genes 
associated with asthma those for allergic rhinitis are rather few, 
limited to family genome wide association studies as well as single 
nucleotide polymorphisms. Furthermore, these studies have not 
been well replicated, had been done on small subject numbers, 
and often the subjects had co-morbid asthma or atopic dermatitis. 
An association with polymorphisms of the transcription factor 
GATA binding protein 3; trans-acting T-cell-specific transcription 
factor and interleukin (IL)-13 with the risk of developing allergic 
rhinitis was reported in a cohort of children followed up until the 
age of 10. Further studies are needed to identify candidate genes 
for allergic rhinitis. 
There is increasing evidence pointing to the influence of prenatal 
and early life exposures on the development of allergic disease. 
Transient environmental pressures can have permanent effects on 
gene regulation and expression through epigenetic mechanisms. 
Histone modifications have been associated with degree of 
bronchial hyperresponsiveness and corticosteroid resistance in 
asthma. Epigenetic mechanisms can operate affect differentiation 
of human T cells and modify dendritic cells [10]. Murine studies 
have revealed that a maternal diet rich in methyl donors can 
enhance susceptibility to allergic inflammation in the offspring, 
mediated through increased DNA methylation [11]. Thus current 
evidence supports a role for epigenetics in the development and 
persistence of allergic rhinitis and asthma.
Early and late phase allergic reactions 
After deposition and elution of allergens into the mucus 
layer, the allergens are taken up by antigen presenting cells and 
processed and presented to helper T lymphocytes. Activated 
helper T lymphocytes release cytokines like IL-4 and IL-13 and 
interact with B lymphocytes to induce the synthesis of allergen 
specific IgE. Thereafter, the allergen-specific IgE binds to the high 
affinity receptor for IgE on the surface of mast cells. 
Early phase response
The early or immediate phase response occurs in sensitized 
individuals within min of exposure to the allergen and lasts for 
about 2-3 h. One of the cardinal components of the early phase 
response is the degranulation of mast cells. In the sensitized 
individual mast cells are abundant in the epithelial compartment 
of the nasal mucosa and can be easily activated upon re-exposure 
to the allergens. Upon crosslinking of the allergen specific IgE 
bound to the surface of mast cells by the specific allergen, mast 
cells degranulate and release a variety of pre-formed and newly 
Fig. 1. Chronic allergic respiratory syndrome. Adapted from Stokes JR, 
Casale T. Allergic rhinitis, asthma and Obstructive sleep apnea - the link. 
In: Pawankar R, Holgate ST, Rosenwasser LJ, editors. Allergy Frontiers. Vol. 
3. 2009. p. 129-140.apallergy.org
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formed mediators leading to what is known as the early phase 
response. Histamine, which is the major mediator of allergic 
rhinitis, stimulates the sensory nerve endings of the Vth nerve 
(trigeminal) and induces sneezing. Histamine also stimulates the 
mucous glands causing the secretion of mucous (rhinorrhea) and 
histamine, leukotrienes and prostaglandins acts on the blood 
vessels causing nasal congestion [7]. 
Late phase response
The early phase response is usually followed by the late phase 
response which occurs 4-6 h after antigen stimulation. The late 
phase response is characterized by a prolongation of symptoms 
– sneezing, rhinorrhea but most predominantly a sustained nasal 
congestion which lasts for about 18-24 h. The late phase response 
is predominantly inflammatory in nature and is characterized 
by a inflammatory cellular influx comprising of predominantly T 
lymphocytes, basophils and eosinophils [7]. A variety of mediators 
are released by these cells including leukotrienes, kinins, histamine 
which result in the continuation of the symptoms and the 
development of the late phase. The key to the orchestration of the 
late phase response lies in the production and release of a variety 
of cytokines and chemokines like IL-4, IL-13 from mast cells [12-
14] as these cytokines can upregulate the expression of ‘adhesion 
molecules’ like vascular cell adhesion molecule 1 (VCAM-1) on 
the endothelial cells facilitating the infiltration of eosinophils, T 
lymphocytes and basophils into the nasal mucosa. In addition, 
chemokines like RANTES, eotaxin, MCP-4 and Thymus-and 
activation Regulated chemokine (TARC) released from epithelial 
cells serve as chemoattractants for eosinophils, basophils and T 
lymphocytes [15-18] (Fig. 2). Other cytokines like granulocyte-
macrophage colony stimulating factor (GM-CSF) released largely 
by epithelial cells and IL-5 from mast cells and T lymphocytes 
prolong the survival of the infiltrated eosinophils in the nasal 
mucosa [14]. More recently, mast cells have been found to further 
contribute to the late phase response through the histamine/
tryptase-induced upregulation of GM-CSF and RANTES in nasal 
epithelial cells and the synergetic action of IL-4/IL-13 and TNF-α-
inducing the upregulation of eotaxin and TARC production in nasal 
epithelial cells [19] (Fig. 2). In addition, a variety of other mediators 
released like eosinophil cationic protein (ECP), platelet activating 
factor, major basic protein (MBP) are also implicated in the late 
phase response. 
Inflammatory cells and their regulation of allergic inflamma-
tion
Mast cells play a central role in the immune mechanisms of 
Fig. 2. Ongoing inflammation in allergic rhintis. Adapted from Pawankar R et al. Curr Opin Allergy Clin Immunol 2002;2:1-5. apallergy.org
Pawankar R, et al. 
Asia Pacific
allergy
http://dx.doi.org/10.5415/apallergy.2011.1.3.157 160
allergic rhinitis. Irani et al. [20] were the first to classify human mast 
cells into two phenotypically distinct subpopulations based on the 
type of neutral proteases they express, namely MC (T) that contain 
only tryptase, and MC (TC) that contain chymase, cathepsin G and 
carboxypeptidase in addition to tryptase. In patients with allergic 
rhinitis mast cells mast cells are found to abundantly accumulate 
in the epithelial compartment of the nasal mucosa [21] and these 
are predominantly of the MC (T) phenotype [21]. Recently the 
factors that induce the selective accumulation of mast cells into 
the allergic nasal epithelium has been of considerable interest 
to several researchers. Nillson et al. [22] have suggested stem 
cell factor (SCF) as the key molecule and Salib et al. [23] have 
suggested that TGF-β is implicated in this mast cell migration. 
We have shown that RANTES is the key molecule regulating the 
migration of mast cells into the allergic nasal epithelium [13] (Fig. 
2).
In addition to the conventionally known mast cells mediators 
released when activated by an IgE-dependent mechanism in 
allergic rhinitis, mast cells release a variety of cytokines such as IL-
4, IL-5, IL-6, IL-8, IL-10, IL-13 and TNF-α [12, 24, 25]. Furthermore, 
mast cells in patients with allergic rhinitis express higher levels of 
very-late activation antigen-4 and 5 and mast cell − extra cellular 
matrix interactions upregulate cytokine secretion from these cells 
[14]. Such a mechanism may contribute to the enhancement of 
mast cell activation especially when the levels of antigen in the 
microenvironment are rather low and contribute to nasal hyper-
responsivess [14]. Mast cells also induce IgE synthesis in B cells [28] 
and as will be described later in this article, mast cells play a key 
role via the IgE-IgE receptor mast cell cascade [19, 27]. Thus, mast 
cells are not only effector cells of the immediate phase response, 
but also act as immunoregulatory cells of the late phase allergic 
reaction as well as on-going allergic inflammation.
Like mast cells, basophils are also key cells in allergic 
inflammation and are derived from pluripotent CD34+ 
hematopoietic progenitor cells [28]. While human basophils 
ordinarily do not reside in peripheral tissues and are therefore 
not detected in the normal nasal mucosa, they are detected in 
the nasal secretion of patients with allergic rhinitis. The number 
of basophils in the nasal secretion correlate with the severity of 
disease. Basophils release histamine, but not tryptase or PGD2, 
and cytokines like IL-4 and IL-13 in response to FcεRI-dependent 
activation and are mainly implicated in the late phase allergic 
response. 
Eosinophils play an important role in chronic allergic diseases 
[29], making them major targets for basic and therapeutic 
research. Eosinophils derive from the bone marrow from a 
progenitor cell (CD34+) that may develop into either eosinophils 
or basophils [30]. Eotaxin appears to be critical for the maturation 
and release of eosinophils from the bone marrow. Chemokines 
such as RANTES and eotaxin [30-35] also induce eosinophil 
recruitment and possibly their activation. Within the tissue, 
cytokines like IL-5 and GM-SCF keep eosinophils alive for several 
days or even weeks which overcome programmed cell death 
(apoptosis) [36, 37]. Mature eosinophils contain MBP [38], ECP [39], 
eosinophil-derived neurotoxin (EDN) [40], eosinophil peroxidase 
all of which play important roles in the immune mechanisms of 
allergic inflammation, especially in altering the surface epithelium. 
In addition, eosinophils synthesize and release cytokines such as 
IL-3, IL-5, GM-CSF [41], proinflammatory cytokines, chemokines 
(RANTES, IL-8, MIP-1α) [42] that play crucial roles in the late phase 
and on-going allergic inflammation. 
Wang et al. [43] studied ECP in nasal secretions in 18 atopic 
patients and 10 healthy volunteers. Allergen challenge in these 
atopics induced an increase in eosinophils that persisted for 10 
h and was less at 24 h, whereas levels of ECP in these atopics 
peaked at 24 h indicating possible degranulation [43]. In another 
study by the same researchers, examined the correlation between 
the symptoms and the levels of the inflammatory cells in nasal 
secretions of 18 seasonal allergic rhinitis patients (group 1) outside 
the pollen season and 40 symptomatic patients (group 2) with 
seasonal allergic rhinitis during the pollen season. Ten non-
allergic subjects (group 3) were also studied as a normal control 
group. In group 1, 94% patients had an immediate response 
of nasal symptoms accompanied by a significant increase of 
histamine, leukotriene C4 (LTC4), and tryptase 5 min after nasal 
allergen challenge (NAC). One h later, a simultaneous increase was 
seen both in the percentage of the eosinophils and in the ECP 
concentration. The eosinophil count reached a peak 2 h after NAC 
with a duration of 8 h, while the highest ECP level reached only 
after 24 h with no clear-cut plateau. In group 2, a high percentage 
of eosinophils was observed. Mostly one observed significantly (p 
< 0.01) higher concentrations of ECP, LTC4 and histamine but not 
of tryptase than the baseline values of group 1. 
In our study of nasal secretions from 20 patients with allergic 
rhinitis and 15 patients with infectious rhinitis by transmission 
electron microscopy we found that the cell population of the 
allergic group consists of (in order of predominance): eosinophils, 
neutrophils, lymphocytes, basophilic cells (basophil leukocytes apallergy.org
Allergic rhinitis: pathomechanisms 
http://dx.doi.org/10.5415/apallergy.2011.1.3.157 161
and mast cells), epithelial cells, and macrophages [42]. In the 
infectious group the population contains: neutrophils, epithelial 
cells, macrophages, and lymphocytes. Marked degranulation was 
found in the eosinophils in allergic nasal secretions. Arzuaga et al. 
[44] studied kinetics of eosinophils in nasal secretion after antigen 
challenge. They demonstrated that eosinophils of 4.9% at baseline 
had increased to 13% at the 30 min, 19% at 2 h and 28%, 8 h after 
the antigenic initiation. On the other hand, the percentage of 
polymorphonuclear cells was of 40.6%, 34.2%, 34.8% and 31.7% 
respectively [44]. 
T lymphocytes are among the principal factors that regulate 
and co-ordinate immune responses in allergic diseases. Th1 T 
cells release predominantly IFN-γ and IL-2 and are involved in the 
delayed hypersensitivity immune reactions, and Th2 T cells release 
predominantly IL-4 and IL-5 and are predominantly involved in 
IgE-mediated allergic inflammation. The ligand for the chemokine 
TARC, CCR4, was found to be expressed by Th2 cells. The attraction 
of Th2 cells by TARC could represent a key mechanism in allergic 
reactions as a strong correlation between the levels of TARC in 
the nasal mucosa and CD4+ CCR4+ cells has been demonstrated 
[45]. Mucosal inflammation in allergic rhinitis is characterized by 
the tissue infiltration of T lymphocytes (CD4+ T cells, and CD25+ 
(activated) T cells) both in the submucosa and the epithelium 
[46, 47]. There is a significant correlation between the increase in 
CD4+ T cells during the late phase allergic reaction following an 
allergen challenge and the number of infiltrating eosinophils in 
the mucosa [48]. This is associated with an increased expression 
of IL-3, IL-4, IL-5, GM-CSF at mRNA levels in the nasal mucosa [49]. 
In perennial rhinitis, there is an increase in CD4+ T memory cells, 
CD4+ T cells and B cells in the nasal mucosa [47]. This is associated 
with an increase in the number of IL-4, IL-5 and IL-13 positive cells 
suggesting a Th2 pattern [50]. Moreover, there is an increase in 
intra-epithelial γ/δT cells in perennial allergic patients [51]. γ/δT 
cells are of importance since they are able to regulate allergic 
immune responses through their capacity to induce IgE synthesis 
by B cells [52].
The Regulatory T (Treg) cell is one of subsets of CD4+ cells, 
which suppresses the functions of other lymphocytes and are 
characterized by surface expression of CD4 and CD25 and nuclear 
expression of the transcription factor forkhead box P3 (FOXP3). 
Recently, many functions of forkhead box P3 and its influence 
on the immune system have been elucidated. T-regulatory cells 
can influence the development and expression of atopy and 
the allergic response. Adaptive FOXP3+ Treg cells were essential 
for establishing mucosal tolerance and for suppressing IL-4 
production. Studies have reported about decreased expression of 
FOXP3 in asthma and allergic rhinitis [53, 54]. The number of Tregs 
increase after immunotherapy suggesting clearly that Tregs play 
an important role in inducing tolerance. Clinical improvement seen 
after allergen immunotherapy for allergic diseases such as rhinitis 
and asthma is associated with the induction of IL-10 & TGF-β 
producing Tr-1 cells as well as FOXP3 expressing IL-10 T cells, with 
resulting suppression of the Th2 cytokine milieu. Activation and 
expansion of antigen-specific CD4+ CD25+ T(regs) using adjuvants 
or pharmacological agents such as low dose steroids or vitamin 
D3 could induce antigen-specific tolerance in allergic diseases. In 
the nasal mucosa of patients with perennial allergic rhinitis, B cells 
comprise about 20% of the total lymphocyte population [47] and 
recent studies have shown that B cells in seasonal allergic rhinitics 
can undergo class switch to IgE locally in the nasal mucosa. 
Allergic reactions occur in a mucosal environment that is rich 
in both dendritic cells and macrophages. However, there are 
significant differences between the lower and upper airways, as 
alveolar macrophages form more than 90% of the cell population 
in bronchial alveolar lavage [55], but airway macrophages on the 
nasal epithelial surface just account for about 1 to 2% of the cells. 
Still, in seasonal and perennial allergic rhinitis, a significant increase 
in macrophages has also been found in the nose [56]. Langerhans 
cells represent an important group of dendritic cells in the nose, 
characterised by the expression of CD1 and Birbeck granules [57]. 
These cells increase after allergen challenge or in patients with 
allergic rhinitis [58] and may serve as antigen presenting cells in 
the upper airway. 
Structural cells in allergic inflammation
For many years epithelial cells were considered to play a 
simple role of a barrier while being involved in the secretion 
of mucus or removal of foreign agents by their cilia. However, 
recent studies have shown that epithelial cells have a much wider 
range of immunomodulatory activities through the release of 
eicosanoids, endopeptidases [59, 60], cytokines and chemokines 
(IL-6, IL-8, GM-CSF, TNF-α, RANTES, TARC, eotaxin, SCF) [61, 62] 
and expression of adhesion molecules like intercellular adhesion 
molecule-1 and VCAM-1 thus contributing to the enhancement of 
allergic inflammation. Furthermore, nasal epithelial cells in allergic 
rhinitics release express and release matrix metalloproteases 
matrix metalloproteinase (MMP)-2, MMP-9 and MMP-13 [63]. Nasal 
epithelial cells express HLA-DR, and CD86 and can present antigen apallergy.org
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to T cells [64]. Also these cells express the alpha and gamma 
subunits of the FcεRI [65]. 
It is now appreciated that allergens, on account of their 
enzymatic proteolytic activity can directly activate cells [66]. House 
dust mite allergens have been shown to activate epithelial cells 
in vitro, inducing cytokine and chemokine release and thus can 
induce airway inflammation independent of IgE [67, 68]. Moroever, 
Der p1 is able to alter the epithelial tight junctions [69] thereby 
increasing epithelial permeability. The relative importance of non-
IgE to IgE-mediated mechanisms is undetermined. It has also been 
shown that epithelial cells in allergic individuals are more sensitive 
to air pollutants like diesel exhaust particles and this has been 
attributed to the greater constitutive and pollutant induced release 
of pro-inflammatory cytokines [70]. 
Epithelial cell-derived thymic stromal lymphopoietin (TSLP) 
is a master switch for asthma or atopic dermatitis by inducing 
a dendritic cell-mediated Th2-type allergic inflammation [71]. 
More recently, studies have shown an overexpresson of TSLP in 
allergic rhinitis and asthma as well as nasal polyps especially in the 
epithelium [72-74]. The epithelial TSLP expression was reduced 
in Fc receptor gamma chain (FcγR)-deficient mice, where the 
high-affinity IgE receptor (FcεRI) is not expressed on mast cells, 
in comparison with control C57BL/6 mice indicating that mast 
cells regulate the epithelial TSLP expression in allergic rhinitis 
possibly via FcεRI, expression. IL-25 is a member of the IL-17 family. 
Upregulate IL-25 can amplify on-going allergic inflammation buy 
upregulating Th2 type inflammation [75]. IL-33 of the IL-1 family 
also can amplify Th2 type inflammation. Increased levels of IL-33 
have been reported in asthma [76].
Infiltration of effector cells is crucial to the development of 
allergic diseases like asthma and allergic rhinitis. Structural cells like 
endothelial cells appear to play a dual role in the pathogenesis of 
allergic rhinitis by participating in the recruitment of leukocytes 
to the site of the allergic response. Endothelial cell VCAM-1 is 
overexpressed during the pollen season [77]. Endothelial cells 
in allergic rhinitics and are also an important source of several 
cytokines and chemokines like RANTES and eotaxin [78]. Moreover, 
like epithelial cells, endothelial cells also express the H1 receptor 
and stimulation with histamine induces activation of these cells 
[79, 80].
Ongoing inflammation in allergic rhinitis 
Structural cells like epithelial cells, residential cells like mast cells 
and the infiltrated inflammatory cells like eosinophils, basophils 
and T cells all play a role in inducing and maintaining on-going 
allergic inflammation. While cytokines like IL-4, and IL-13 released 
from mast cells and T cells help drive B cells toward IgE synthesis 
and could contribute to the local IgE synthesis in the nasal mucosa 
of patients with allergic rhinitis [19, 26, 27]. Most recent studies also 
have shown that under allergic inflammatory conditions, “primed” 
mast cells express high levels of the high affinity receptor for IgE 
and the ligand for the surface antigen CD40, involved in T/B cell 
interactions leading to IgE production [26, 27]. Mast cells also have 
the potential to function as antigen presenting cells [81] and IL-4 
from mast cells can direct uncommitted helper T lymphocytes 
toward Th2 and also upregulate the FcεRI expression in mast 
cells and basophils [26]. These findings suggest that mast cells 
can orchestrate on-going allergic inflammation. Furthermore, the 
locally synthesized IgE itself can upregulate the FcεRI expression 
in mast cells [26, 27]. The augmented FcεRI in mast cells can 
bind increased number of IgE-Ag complexes which in turn can 
enhance the sensitivity of mast cells to allergen resulting in the 
enhancement of the production of immunomodulatory cytokines 
and chemical mediators, forming an important positive-feedback 
amplification loop involving the IgE-IgE receptor mast cell cascade 
(Fig. 2). 
 
Local IgE production
The production of IgE locally in the nasal mucosa is now well 
established. Studies have shown both by in-vivo allergen change 
experiments done out of season in ragweed sensitive patients 
that there is IgE class switch and increase in IL-4 positive cells 
[82]. Similarly in-vitro allergen challenge studies have shown the 
upregulation of IgE producing B cells [83]. The locally produced 
IgE then can play a key role in mast cell activity amplification via 
upregulating the FcεRI expression in mast cells and subsequent 
mediator release after crosslinking of the bound IgE [27]. Recent 
studies have also shown the presence of local IgE in idiopathic 
rhinitis suggesting the possibility of local IgE production playing a 
more important role in on-going allergic inflammation [84].
 
Nasal hyperresponsiveness 
Patients with allergic rhinitis report increased symptomatic 
responsiveness to environmental irritants such as tobacco smoke 
compared with nonatopic individuals. A hallmark of allergic rhinitis 
is hyperresponsiveness of symptomatic individuals to specific 
allergens, a phenomenon known as ‘priming’, and to nonspecific 
stimuli such as irritant particles and strong odors; however, the apallergy.org
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causes of this effect remain unclear. Activated inflammatory 
cells may foster mucosal penetration by allergen and provide 
additional targets for antigen-specific stimulation. Increased 
generation of inflammatory mediators also are expected to do 
so. In symptomatic patients, hyperresponsiveness to nonspecific 
irritants may reflect interactions among inflammatory cellular 
influx, epithelial injury, and increased end-organ responsiveness 
caused by exposure to an antigen.
Nerve growth factor (NGF) which is over expressed in allergic 
rhinitis is linked to the development of hyperresponsiveness, and 
is also associated with allergic inflammation, thus bridging the gap 
between these two features of allergic rhinitis and asthma. NGF is 
synthesized, stored, and released by cells that play key roles in the 
allergic inflammatory disease of the airways, including mast cells, 
eosinophils, CD4+ T cells, B cells, and respiratory epithelial cells 
[85]. Mast cells express and secrete NGF [85, 86], and they have 
been shown to be in close apposition with tachykinin-containing 
nerve endings in peripheral tissue [87]. Other cells in the later 
phases of inflammation may also contribute to NGF release in the 
human airways, based on NGF elevation in bronchoalveolar lavage 
fluids 18 h after segmental allergen challenge in asthmatics [88].
Minimal persistent inflammation
There is evidence of ongoing inflammation in the airway even 
when rhinitis or asthma symptoms are quiescent. This has had 
important implications for the way we treat and has led to the 
concept of the need for long term anti-inflammatory treatment for 
those with rhinitis and asthma [89]. 
Systemic inflammation in allergic rhinitis
AR is not associated with just localized inflammation of the nasal 
mucosa but also has a systemic element to it. This may explain in 
a significant way the mechanisms underlying the rhinitis–asthma 
link. In individuals with seasonal allergic rhinitis without co-existent 
asthma, nasal allergen provocation produced increased adhesion 
molecule expression, eosinophil infil tration in both the upper and 
lower airways, and increased bronchial hyper-reactivity [90, 91]. 
These results demonstrate that an allergic nasal reaction produces 
systemic inflammatory changes. In sensitized subjects, allergen 
exposure activates immune cells, including Th2 lymphocytes, 
dendritic cells, mononuclear cells, mast cells, and others, both 
within the nose and in nasal-associated lymphatic tissues. Some of 
these Th2 cells migrate to the bone marrow, where they stimulate 
the bone marrow to produce and recruit the inflammatory cells, 
including basophils, eosinophils and mast cell precursors, to the 
inflamed target tissues. 
Link between allergic rhinitis and asthma
The increasing evidence on the links between AR and asthma 
comes from epidemiologic, immunologic, and clinical studies. 
Epidemiologically, up to 40% of patients with AR also have 
asthma, and up to 80% of patients with asthma experience nasal 
symptoms. Furthermore, patients with AR are at three times 
the risk of developing asthma compared with those without 
AR and in children who develop rhinitis within the first year of 
life the chances of developing asthma are twofold greater as 
compared with those who develop rhinitis later in life. Therapeutic 
outcomes of treating AR in asthma have shown that AR treatment 
improves asthma symptoms and lowers overall costs and reduces 
hospitalizations [92]. In a recent international survey on the impact 
of concomitant AR and asthma on patient health and quality of 
life, the presence of AR in children with asthma disrupted their 
lives by limiting their ability to get a good night’s sleep (79% of 
adults and children), participate in leisure and sports (75% of adults 
and children), concentrate at work/school (69% of adults and 73% 
of children), or enjoy social activities (57% of adults and 51% of 
children), worsened [93].
Both AR and asthma are inflammatory diseases and their 
inflammatory mechanisms are similar in that they are characterized 
by an inflammatory infiltrate made up of eosinophils, T cells, 
and mast cells that release several mediators, chemokines and 
cytokines, local and systemic IgE synthesis, and a systemic link 
via the bone marrow. Typical early- and late-phase responses 
are also cardinal features common to both rhinitis and asthma. 
Studies have shown that patients with AR exhibit bronchial hyper-
responsiveness and increase in inflammatory cells, and that 
nasal allergen challenge further increases this hyper-reactivity. 
Eosinophils have been demonstrated in the nasal mucosa of 
patients with asthma, even in the absence of symptoms of 
rhinitis. In addition, patients with AR have increased number of 
inflammatory cells in their bronchial mucosa. This increase in 
bronchial inflammation in response to allergen-induced rhinitis 
might contribute to the exacerbations of asthma frequently seen 
in individuals with underlying AR. Allergen challenge increased 
the bone marrow concentrations of both cytokines and progenitor 
cells both in animal models and in individuals with atopic asthma 
and in addition, in atopic individuals who had late asthmatic 
responses and airway eosinophilia, allergen inhalation caused apallergy.org
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trafficking of T lymphocytes to the bone marrow, enhancing the 
ability of these lymphocytes to generate IL-5. Ultimately, these 
newly generated inflammatory cells enter the circulatory system, 
from where they are selectively recruited to the target organs 
(lungs and nose), exacerbating airway inflammation. In addition 
to stimulating inflammatory cell production, cytokines up-
regulate the expression of adhesion molecules, further facilitating 
the recruitment of inflammatory cells into nasal and bronchial 
tissues. This selective recruitment of inflammatory cells into the 
airways would occur only in individuals with pre-existing asthma 
in whom specific adhesion molecules, such as VCAM-1, and 
chemoattractants, such as eotaxin, already exist. Persons without 
asthma do not have these addressins in their airways and thus 
do not have the machinery in place to recruit inflammatory cells 
into their airways during exacerbations of rhinitis. This parallel 
relationship is influenced by many interactions between the nose 
and the lower airways: some interactions stem from the fact that 
the nasal passages play a major homeostatic role by conditioning 
inhaled air, but perhaps even more important is the bidirectional 
interaction that results from the systemic inflammation that is 
produced after local allergic reactions. 
CONCLUSION
Allergic rhinitis is characterized by an inflammatory infiltrate 
made of different cells. This cellular response includes the 
chemotaxis, selective recruitment and transendothelial migration 
of cells, the localization of cells within the different compartments 
of the nasal mucosa, the activation and differentiation of various 
cell types as well as a prolongation of their survival, the release 
of mediators by these activated cells, the regulation of the local 
and systemic IgE-synthesis and the communication with the 
immune system and the bone marrow. These events take place 
only in subjects who have been sensitized to allergens before, i.e. 
allergen-specific IgE-antibodies have been formed and bound 
to the membrane of mast cells and other cells, but not in healthy 
individuals, who do not show a measurable reaction of the nasal 
mucosa to the same allergens. 
Although, histamine, (released by mast cells and basophils), 
is still one of the major effectors of the allergic reaction, with 
the increasing knowledge and better understanding of the 
mechanisms of the allergic reaction, many other mediators 
produced by different cell types are found to be involved. Thus, 
the intricate interaction amongst these mediators, cytokines, 
chemokines, neuropeptides, adhesion molecules and various cells 
in the form of a complex network lead to the onset of specific 
symptoms and the non specific hyperreactivity of allergic rhinitis. 
The pathophysilogy of allergic rhinitis may be further complicated 
by the involvement of neural reflex mechanisms and interaction of 
allergic and non-allergic stimuli. 
The vast majority of patients with asthma have rhinitis, and 
rhinitis is a major independent risk factor for asthma in cross-
sectional and longitudinal studies. The relationships between 
rhinitis and asthma can be viewed under the concept that the two 
conditions may be manifestations of one syndrome, the ‘chronic 
allergic respiratory syndrome’, occurring in two different parts of 
the respiratory tract. Some interactions arise from the fact that 
the nasal passages play a major homeostatic role by conditioning 
inhaled air, but perhaps even more important is the bidirectional 
interaction that results from the systemic inflammation that is 
produced after local allergic reactions. Although there are cardinal 
structural differences between the nose and the lungs, these 
experimental and real-life observations on the link between 
rhinitis and asthma outweigh the differences and lend support 
to the concept that rhinitis and asthma may be considered 
as manifestations of one syndrome that has a wide spectrum 
of severity. Successful management of this chronic allergic 
respiratory syndrome requires an integrated view of the airways, 
understanding of their interactions, and an integrated approach of 
treatment also targeting systemic inflammation.
Finally, the understanding that the mechanisms of disease 
generation provide a framework for rational therapy in this 
disorder, which will be based on the complex inflammatory 
reaction rather than on the symptoms alone is very important 
to the development of newer and more effective strategies of 
treatment. 
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